U.K.'s NICE recommends Sirtex's microsphere for liver cancer

2017 01 26 12 32 44 153 Check Mark 400

The U.K. National Institute for Health and Care Excellence (NICE) gave radiation oncology firm Sirtex Medical positive guidance on the use of its selection internal radiation therapy (SIRT) with SIR-Spheres yttrium-90 microspheres for the treatment of adults with unresectable advanced hepatocellular carcinoma (HCC).

The NICE recommends SIR-Spheres in England and Wales as a fully funded and reimbursed option for adult patients with HCC if it's used in people with Child-Pugh grade A liver impairment when conventional transarterial therapies are inappropriate.

Also, the company must provide SIR-Spheres according to the commercial arrangement, the NICE said.

Page 1 of 549
Next Page